Why Did Cathie Wood Just Buy 230,000 Shares of Kodiak AI Stock, and Should You?
Artificial intelligence (AI) has been doing more than powering chatbots and cloud software. It is also starting to reshape industries that still depend on freight, logistics, and long-haul trucking. That is one reason investors have been watching Ark Invest so closely lately, as Cathie Wood keeps leaning into AI names tied to real-world automation.
» Read more about: Why Did Cathie Wood Just Buy 230,000 Shares of Kodiak AI Stock, and Should You? »
Read MoreU.S stock market today: S&P 500, Nasdaq make gains but Dow Jones fall. Here's what to expect on Wednesday
U.S. stocks swung sharply Tuesday as uncertainty about the war with Iran increased ahead of a looming deadline set by President Donald Trump to destroy Iranian power plants and bridges. S&P 500 fell as much as 1.2 per cent. The S&P 500 erased all its losses and ended with a modest gain of 0.1 per cent.
Read MoreStock market today: Dow S&P 500, Nasdaq futures surge on news of a two-week ceasefire
US stock futures pushed higher Tuesday evening as markets reacted to news of a two-week ceasefire between the US-Israel coalition and Iran, announced by Trump via Truth Social.
Futures linked to the S&P 500 (ES=F) climbed 1.5%, while Nasdaq 100 (NQ=F) contracts popped 1.7%.
Read MoreBill Ackman’s $64 billion Universal Music play is part of his strategy to become the next Warren Buffett
Billionaire investor Bill Ackman’s hedge fund, Pershing Square Capital, is planning to buy Universal Music Group (UMG), the world’s largest music company, which represents artists including Taylor Swift, Bad Bunny, Bob Dylan, and the Beatles.
The $64 billion pitch announced Tuesday is Ackman’s latest move to turn Pershing into a “modern-day” Berkshire Hathaway and make Ackman the next Warren Buffett.
Read MoreCheck best interest rates offered in April by banks and housing finance companies
The latest policy stance by the Reserve Bank of India further reinforces this need for careful evaluation.
The Burst
Massive Upside In Big Money Pharma Favorite?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes in the use of immune therapies for cancer treatment. Specifically, Iovance is exploring new applications of tumor infiltrating lymphocyte (TIL) therapy, utilizing cells that the human body naturally produces to attack cancerous tumors.
There was lots of hype about this next-generation cancer treatment company but its share price has been decidedly lackluster this year,
» Read more about: Massive Upside In Big Money Pharma Favorite? »
Read MoreThe Ivy
Will This ETF 2x Before Year End?
In recent months, some of the most sophisticated investors on Wall Street have made a bold move by pouring hundreds of millions into BlackRock’s iShares Bitcoin Trust (IBIT).
This isn’t just a passing trade but a conviction bet that Bitcoin’s best days may still be ahead and while still trading under $100,000 per coin,
» Read more about: Will This ETF 2x Before Year End? »
Read MoreThe Spotlight
Why This Beverage Giant Can’t Be Toppled
A famous book on business was titled Barbarians at the Gate, documenting the leveraged buyout of RJR Nabisco. If nothing else, it highlights how just the sniff of an opportunity to make money can drive money seekers to make wild decisions.
Some giant businesses have been on the receiving end of similar threats to their solvency as invaders attempt to take their share.
» Read more about: Why This Beverage Giant Can’t Be Toppled »